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 In the past few years, we have examined precisely the
intraocular and systemic biodistribution of fluorescent anti-
gens (Ag) injected into the anterior chamber (AC) of the rat
eye. We and others have shown that fluorescent Ag is inter-
nalized predominantly by macrophages [1] located in the tis-
sues lining the eye (such as the cornea, iris, ciliary body) and
also by macrophages located in the conjunctiva [1,2]. We re-
ported that soluble Ag reach the marginal zone of the spleen
where they are internalized by resident ED3-positive macroph-
ages via passage through the trabecular meshwork and
Schlemm’s canal [3]. In addition, we demonstrated that fluo-
rescent Ag located in the conjunctiva is drained by conjuncti-
val lymphatic vessels to cervical LN where it is captured by
ED3-positive subcapsular sinus macrophages [3-5]. These
macrophages are in contact with B and T lymphocytes and are
thus potentially able to modulate the immune reactivity of these
cells [3].
In humans, intravitreal (IVT) injection is routinely used
for the intraocular delivery of therapeutic molecules [6,7].
However, to avoid repeated IVT injections, novel delivery
systems are tested to improve safety and effectiveness [8-11].
Intraocular and systemic biodistribution of molecules injected
intravitreally and the egress pathways of molecules originat-
ing from the vitreous could have important implications for
the design of therapeutic strategies of ocular inflammation
based on IVT injection.
Vasoactive intestinal peptide (VIP) [12] is a 28 amino acid
immunomodulatory neuropeptide constitutively expressed in
the eye and involved in the induction and maintenance of ocular
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Purpose: Local delivery of therapeutic molecules encapsulated within liposomes is a promising method to treat ocular
inflammation. The purpose of the present study was to define the biodistribution of rhodamine-conjugated liposomes
loaded with vasoactive intestinal peptide (VIP), an immunosuppressive neuropeptide, following their intravitreal (IVT)
injection in normal rats.
Methods: Healthy seven- to eight-week-old Lewis male rats were injected into the vitreous with empty rhodamine-
conjugated liposomes (Rh-Lip) or with VIP-loaded Rh-Lip (VIP-Rh-Lip; 50 mM of lipids with an encapsulation effi-
ciency of 3.0±0.4 mmol VIP/mol lipids). Twenty-four h after IVT injection, the eyes, the cervical, mesenteric, and in-
guinal lymph nodes (LN), and spleen were collected. The phenotype and distribution of cells internalizing Rh-Lip and
VIP-Rh-Lip were studied. Determination of VIP expression in ocular tissues and lymphoid organs and interactions with T
cells in cervical LN was performed on whole mounted tissues and frozen tissue sections by immunofluorescence and
confocal microscopy.
Results: In the eye, 24 h following IVT injection, fluorescent liposomes (Rh-Lip and VIP-Rh-Lip) were detected mainly
in the posterior segment of the eye (vitreous, inner layer of the retina) and to a lesser extent at the level of the iris root and
ciliary body. Liposomes were internalized by activated retinal Müller glial cells, ocular tissue resident macrophages, and
rare infiltrating activated macrophages. In addition, fluorescent liposomes were found in the episclera and conjunctiva
where free VIP expression was also detected. In lymphoid organs, Rh-Lip and VIP-Rh-Lip were distributed almost exclu-
sively in the cervical lymph nodes (LN) with only a few Rh-Lip-positive cells detected in the spleen and mesenteric LN
and none in the inguinal LN. In the cervical LN, Rh-Lip were internalized by resident ED3-positive macrophages adjacent
to CD4 and CD8-positive T lymphocytes. Some of these T lymphocytes in close contact with macrophages containing
VIP-Rh-Lip expressed VIP.
Conclusions: Liposomes are specifically internalized by retinal Müller glial cells and resident macrophages in the eye. A
limited passage of fluorescent liposomes from the vitreous to the spleen via the conventional outflow pathway and the
venous circulation was detected. The majority of fluorescent liposomes deposited in the conjunctiva following IVT injec-
tion reached the subcapsular sinus of the cervical LN via conjuntival lymphatics. In the cervical LN, Rh-Lip were internal-
ized by resident subcapsular sinus macrophages adjacent to T lymphocytes. Detection of VIP in both macrophages and T
cells in cervical LN suggests that IVT injection of VIP-Rh-Lip may increase ocular immune privilege by modulating the
loco-regional immune environment. In conclusion, our observations suggest that IVT injection of VIP-loaded liposomes
is a promising therapeutic strategy to dampen ocular inflammation by modulating macrophage and T cell activation
mainly in the loco-regional immune system.
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2263immune privilege [13]. VIP modulates the activity of mac-
rophages [14], dendritic cells [15,16], and T lymphocytes
[17,18] in vitro and in vivo. Injection of VIP in vivo also in-
duces the differentiation of regulatory dendritic cells and regu-
latory T cells [19,20]. Recently, we reported that IVT injec-
tion of VIP encapsulated in sterically-stabilized liposomes
(VIP-Lip) could be used in immunosuppressive therapies of
ocular inflammations [21].
The aim of the present study was to determine: (1) the
intraocular and systemic biodistribution of empty rhodamine-
conjugated liposomes (Rh-Lip) or VIP loaded Rh-Lip (VIP-
Rh-Lip) 24 h following their IVT injection into healthy rats
and (2) the nature of cells that internalize Rh-Lip and VIP-
Rh-Lip in the eye and secondary lymphoid organs. Our re-
sults suggest that IVT injection of VIP-loaded liposomes could
modulate the activation of macrophages and glial cells in the
eye as well as macrophages and T lymphocytes in the cervical
LN draining the ocular adnexae.
METHODS
Animals:  Eight-week-old male Lewis rats weighing around
280 g (R. Janvier, Le Genest Saint Isle, France) were used.
Animals were maintained in a 12 h light, 12 h dark cycle.
Food and water were supplied ad libitum. Three experiments
using a total of 14 healthy rats were performed to study the
biodistribution of rhodamine-conjugated liposomes (Rh-Lip)
and rhodamine-conjugated VIP-loaded liposomes (VIP-Rh-
Lip). Animals were handled and cared for in compliance with
the ARVO Statement for the Use of Animals in Ophthalmic
and Visual Research.
Liposome preparation:  rhodamine-conjugated pegylated
(PEG) liposomes were composed of phosphatidylcholine (PC),
phosphatidylglycerol (PG), cholesterol (Chol) and 1,2-
distearoyl-sn-glycero-3-phosphoethanol-amine-N-[methoxy-
poly -(ethyleneglycol)-2000] (PEG-DSPE) and phosphatidyle-
thanolamine-N-(lissamine rhodamine B sulfonyl; PE-Rh). The
final molar ratio was PC:PG:Chol:PEG-DSPE:PE-Rh
(47:10:35:5:3, respectively). Liposomes were prepared by the
thin-film hydration method as previously described [21,22].
Physico-chemical characterization of liposomes:  Lipo-
some mean size was determined before and after encapsula-
tion by quasi-elastic light scattering with a Nanosizer N4 Plus
(Beckman Coulter, Margency, France) after having diluted the
suspension 150 times in a saline solution. Measurement con-
ditions were 20 °C, 1 mPa.s, refractory index of 1.33, 1 min
data acquisition, and detection angle of 90°. Measurements
made in triplicate were expressed as mean diameter±standard
deviation. Liposomes presented a size between 300 and 600
nm for VIP-Lip and between 250 and 400 nm for unloaded
Lip.
Zeta potential was measured using a Malvern Zetasizer
Nano ZS (Malvern Instruments, Worcestershire, UK) at 25 °C
following a 1/100 (v/v) dilution in a saline solution (150 mM).
Both VIP-Lip and unloaded Lip presented slightly negative
Zeta potential (-1.7 mV and -0.9 mV, respectively). Because
of the high salt concentration, the distribution plot is not mea-
surable.
The concentration of 28-aa VIP in liposomes was deter-
mined by enzyme linked immuno sorbent assay (ELISA); (VIP
enzyme immunoassay (EIA) kit extraction free, Peninsula
Laboratories Inc., San Carlos, CA). The principle of the assay
is based on the competition between biotinylated VIP and non-
biotinylated peptide (either standard or unknown) to bind on
anti-VIP antibody that recognizes 28-aa VIP. Modifications
were performed in the protocol to quantify VIP in liposome
suspensions instead of in serum or plasma. Liposomes were
solubilized by the addition of sodium dodecyl sulfate (SDS)
1% (1.06 mmol lipids/g SDS). Samples were then diluted in
pH 7.7 buffer to reach VIP concentrations in a range of 0.1-10
ng/mL. The calibration curve was also prepared with pH 7.7
buffer instead of the standard diluent provided by the kit. Re-
sults were expressed as mean±standard deviation. VIP encap-
sulation yield was 37%±7%, corresponding to an encapsula-
tion efficiency of 3.0±0.4 mmol VIP/mol lipids. Final VIP
concentration within liposomes was 0.55 mg/mL.
Intravitreal liposomes injections:  To perform intravitreal in-
jections, Lewis rats were anesthetized by intraperitoneal in-
jection of 0.15 mL (5.47 g/100 ml saline) of Pentobarbital
sodique® (Ceva santé animale, Libourne, France). Pupils were
dilated by instillation of one drop of Tropicamide 5%
(CibaVision Ophthalmics, Toulouse, France). One drop of
Tetracaïne 1% (CibaVision Ophthalmics, Toulouse, France)
was administered for local anesthesia. Intravitreal injections
(IVT) of Rh-Lip (10 µl) were performed in both eyes using
sterile syringes fitted with a 30-gauge needle (Microfine,
Becton Dickinson AG, Meylan, France) as previously de-
scribed [21].
Tissue collection and processing for immuno-histochem-
istry:  Immediately after sacrifice, the eyes, the right and left
submandibular and superficial cervical LN (collectively named
cervical LN), spleen, mesenteric LN, and inguinal LN were
collected and processed for immunohistochemistry as previ-
ously described [21]. All tissues were post-fixed in 4%
paraformaldehyde containing 5% sucrose for 2 h before being
immersed for an additional 2 h in phosphate buffer containing
5% sucrose and finally overnight in phosphate buffer contain-
ing 15% sucrose. The next day samples were embedded and
frozen in optimal cutting-temperature (OCT) compound (Tis-
sue-Tek®, Sakura Finetek, Zoeterwoude, Netherland) and
stored at -80 °C. Frozen sections (10 µm thick) of secondary
lymphoid organs and antero-posterior sections of eyes at the
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TABLE 1. DISTRIBUTION OF RH-LIP REMAINS CONSTANT OVER TIME
Biodistribution of Rh-Lip and VIP-Rh-Lip bearing cells 24 h follow-
ing IVT injection.
2264optic nerve level were cut using a cryostat (Leica CM 3050S,
Wetzlar, Germany) and mounted on gelatin-coated slides for
immunohistochemical analysis.
Immunohistochemistry:  To characterize biodistribution
of Rh-Lip containing cells (red), immunostaining was per-
formed on the frozen eye and secondary lymphoid organ sec-
tions as previously described [1,21]. The slides were incu-
bated with a range of purified mouse monoclonal antibody
(mAb) all purchased from Serotec Ltd. (Oxford, UK) at dilu-
tion 1:50. T lymphocytes were detected with the mAb anti-T
cell receptor (TCR; clone R73), the mAb anti-CD4 (clone W3-
25) recognizing CD4-positive T cells and macrophages in rats
[23] and the mAb anti-CD8 (clone OX8) against CD8-posi-
tive T cells. Macrophages were recognized by incubation with
either the mAb anti-macrosialin CD68 specific of a cytoplas-
mic antigen in rat monocytes, macrophages and dendritic cells
(clone ED1) or mAb anti-sialoadhesin, CD169 (clone ED3)
[24]. Staining of dendritic cells was performed using the mAb
OX-62 (clone OX-62). Secondary Alexa 488 (green)-conju-
gated goat-anti-mouse antibody (Invitrogen, Molecular Probes,
Eugene, OR) was then applied at dilution 1:250. In some ex-
periments, slides were counterstained with biotinylated-mouse
anti-MHC class II mAb (clone OX6; Serotec Ltd.). The
biotinylated mAb were revealed by incubation with Cy5 (in-
frared)-conjugated streptavidin (Interchim, Montluçon, France)
at dilution 1:100. For VIP immuno-detection, sections were
incubated with rabbit anti-VIP polyclonal antibody (Bachem
AG (Merseyside, UK)) at dilution 1:100. Secondary Alexa 488-
conjugated goat anti-rabbit mAb purchased from Interchim
or Alexa 633-conjugated goat anti-rabbit mAb (Invitrogen,
Molecular Probes) was then applied at dilution 1:250. Stain-
ing of Müller cells was performed using a rabbit polyclonal
antibody against glial fibrilary acidic protein (1:100; GFAP)
followed by incubation with Alexa 488-conjugated goat anti-
rabbit mAb (Interchim) at dilution 1:250. In some experiments,
the nucleus was detected by incubation with Toto3®-iodide,
1 mM in di-methyl sulfoxide (DMSO; Invitrogen, Molecular
Probes). In every staining run, negative controls of
immunostaining were performed by incubation of tissues sec-
tions with isotype control (mouse IgG1κ; purified protein,
clone PMP; Serotec) followed by fluorochrome-conjugated
mAb. All controls were negative. No rhodamine fluorescence
was observed on tissue sections from animals that were not
injected with Rh-Lip. Sections were mounted in phosphate
buffered saline (PBS) containing glycerol (50:50, vol:vol).
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Figure 1. Biodistribution and phenotype
of cells internalizing rhodamine-conju-
gated liposomes in the retina and vitre-
ous of normal rats 24 h post IVT injec-
tion of Rh-Lip.  A: On a whole-mounted
retina, some microglial cells stained with
ED1 (green) are detected phagocytosing
limited number of rhodamine-conju-
gated-liposomes (Rh-Lip, red). B:
rhodamine-conjugated-liposomes (Rh-
Lip, red) are internalized by GFAP-posi-
tive (green)-retinal Müller glial cells as
evidenced by colocalization (yellow) in
the internal limiting membrane and the
ganglion cell layer. Fluorescent Rh-Lip
are seen as red fluorescent round dots on
the images while free rhodamine is de-
tected as diffuse red fluorescence within
the ganglion cell layer (an asterisk) and
inner plexiform layer (a double asterisk).
C: On a whole-mounted retina, macroph-
ages expressing ED3 (green) located at
the level of the inner limiting membrane
of the retina internalized Rh-Lip injected
into the vitreous. D: Some of these mac-
rophages express OX6 (green) suggest-
ing they are activated and contain vari-
ous amount of Rh-Lip. D shows a single
OX6-positive macrophage containing a
few Rh-Lip located into its cytoplasm.
Photographs are representative of images
obtained from frozen sections (B) and
whole mounts (A, C, and D) performed
on a total of 12 eyes. All bars represent
20 µm except in D (10 µm). Confocal
optical section, in all images, is 3 µm.
2265Confocal microscopy and image analysis:  Confocal mi-
croscopy was performed using a Zeiss LSM 510 laser scan-
ning confocal microscope equipped with an argon laser giv-
ing 488 nm (blue excitation, green emission), a helium/neon
laser giving 543 nm (green excitation, red emission), and a
helium neon laser giving 633 nm (green excitation, infrared
emission), which allowed three fluorochromes to be observed.
Sections were analyzed at 63X oil immersion objective (Zeiss
plan-Apochromat NA 1.4) and at 40X objective (Zeiss plan
neo fluar N.A 0.75); sequential images were merged and false
colored using Zeiss LSM image browser software to produce
a composite multicolor image. Final image processing was
performed using Adobe Photoshop CS2 (Mountain View,
Canada).
RESULTS
Biodistribution of rhodamine-conjugated liposomes in
ocular tissues and adnexae:  The intraocular distribution of
free Rh-Lip, VIP-Rh-Lip, and resident phagocytes containing
liposomes 24 h post-IVT injection is summarized in Table 1.
No difference in the biodistribution of cells containing Rh-
Lip and VIP-Rh-Lip was observed. Cells containing fluores-
cent liposomes were mainly detected in the posterior segment
of the eye along the retinal inner limiting membrane and in
the vitreous. Liposomes were almost never detected in the reti-
nal parenchyma per se and Rh-Lip were not observed at the
level of the choroid or sclera. However, free rhodamine was
detected within the internal layers of the retina, suggesting
that a release of free VIP in the retinal parenchyma could oc-
cur as well. In the anterior segment of the eye, only a few cells
containing Rh-Lip were seen in the ciliary body. The iris and
cornea were devoid of free Rh-Lip and of cells containing
Rh-Lip. At the level of ocular adnexae, many free Rh-Lip and
cells containing Rh-Lip were located in the conjunctiva and
the episclera.
Phenotypic characterization of intraocular and conjunc-
tival phagocytes internalizing rhodamine-conjugated lipo-
somes (Rh-Lip or VIP-Rh-Lip):  At the level of the internal
retina, rare liposomes were internalized by ED1-positive rami-
fied microglial cells (Figure 1A). More often Rh-Lip were
internalized by activated GFAP-positive Müller glial cells (Fig-
ure 1B). In the vitreous and along the inner limiting mem-
brane of the retina, rare infiltrating cells had taken up lipo-
somes. This observation indicated that liposomes have a mod-
est proinflammatory effect. The cells internalizing liposomes
in the vitreous presented a rounded morphology and were
mostly ED1-positive (data not shown) and ED3-positive (Fig-
ure 1C). A few cells containing Rh-Lip also expressed MHC
class II molecules (OX6; Figure 1D), suggesting that they
correspond to activated macrophages and are capable of Ag
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Figure 2. Biodistribution and phe-
notype of cells internalizing
rhodamine-conjugated-liposomes in
the iris and ciliary body of normal
rats 24 h post IVT injection of Rh-
Lip.  A: On a frozen section of the
iris, resident iridal ED1-positive
(green) and OX6-positive cells
(blue) are negative for fluorescent
liposomes. B: Frozen section of the
ciliary body showing a rare ED1-
positive cell containing liposomes
(arrow), ED1 green, rhodamine-
conjugated-liposomes  red,
colocalization yellow. C: Ciliary
body flat mount with ED1-positive
cells containing fluorescent lipo-
somes (arrows). The white arrow-
head shows liposomes internalized
by an ED1-negative cell. Other fluo-
rescent liposomes appear not to be
internalized by cells (red dots). D:
Uptake of rhodamine-conjugated-li-
posomes by OX6-positive cells
(green) appears limited to a few cells
(arrow), the arrowhead shows lipo-
somes internalized inside an OX6-
negative cell. Photographs are rep-
resentative of images obtained from
frozen sections (A,B) and whole
mounts (C,D) performed on a total
of 12 eyes. All bars represent 20 µm.
Confocal optical section, in all im-
ages, is 1.5 µm.
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Figure 3. rhodamine-conjugated-lipo-
somes and VIP biodistribution in con-
junctiva 24 h following IVT injection of
Rh-Lip and VIP-Rh-Lip.  A: Following
IVT injection, Rh-Lip (red) are internal-
ized by cells in the conjunctival stroma.
Fluorescent liposomes are not detected
in conjunctival epithelium and sclera. Li-
posome concentration is maximal in the
posterior conjunctiva (P.C) near the site
of injection and decreases toward the
anterior conjuntiva (A.C.) and the lim-
bus. No liposomes were detected in the
corneal stroma (data not shown). Nuclei
stained with Toto3®-iodide are depicted
in white. B: OX6-positive dendritic cell
in the epithelium and C: ED3-positive
macrophages in the conjunctival epithe-
lium do not internalize Rh-Lip. D: ED1-
positive cells in the anterior conjunctival
stroma and E: in the posterior conjuncti-
val stroma contain large amount of Rh-
Lip. F: Fluorescent Rh-Lip (red) in the
conjunctival stroma are taken up by ED3-
positive (green), OX6 (blue)-negative
macrophages (arrows). Choroidal ED3
and OX6-positive cells do not contain li-
posomes. G: VIP expression in the con-
junctiva of a rat that received an IVT in-
jection of VIP-Rh-Lip. VIP, detected with
rabbit anti-VIP antibody (green) is local-
ized in cells containing Rh-Lip (red) in
the conjunctiva. Note the extra cellular
green dots representing free VIP not in-
ternalized by cells. VIP appears green,
Rh-Lip appears red and colocalization is
indicated in yellow. All bars represent 20
µm, confocal microscopy optical section
is 1.5 µm in all images. Photographs are
representative of images obtained from
frozen sections (A,F,G) and whole
mounts (B-E) performed on a total of 12
eyes except G that is a representative
image of ocular frozen sections from four
eyes.
2267presentation. The amount of Rh-Lip within the cytoplasm of
these phagocytes was variable; some cells contained only a
low number of Rh-Lip (Figure 1D) while others OX6-posi-
tive cells had their cytoplasm filled with fluorescent liposomes
(data not shown).
In the anterior segment, no uptake of Rh-Lip by ED1 or
OX6-positive cells on the iris was detected (Figure 2A). By
contrast, on the ciliary body, some cells contained Rh-Lip (Fig-
ure 2B). These cells expressed mostly ED1 (Figure 2C) but
rarely MHC class II (OX6; arrow in Figure 2D). A limited
number of infiltrating inflammatory cells were detected in the
aqueous humor confirming the low inflammatory potential of
Rh-Lip.
There was a quantitative gradient of Rh-Lip located in
the ocular adnexae. The highest concentration of fluorescent
liposomes was detected in the posterior conjunctiva (P.C) near
the site of the injection and decreased gradually toward the
posterior episclera and anterior conjunctiva (A.C, Figure 3A).
At the level of the cornea, no Rh-lip could be detected (not
shown). No fluorescent liposomes were detected in the sclera
and corneal and conjunctival epitheliums. Langerhans-like
MHC class II-positive cells in the corneal epithelium (Figure
3B) and ED3-positive macrophages in the conjunctival epi-
thelium did not contain fluorescent liposomes (Figure 3C).
rhodamine-conjugated liposomes were located exclusively in
the conjunctival stroma (Figure 3A) in ED1-positive macroph-
ages in the posterior (Figure 3D) and anterior (Figure 3E) con-
junctival stroma. In addition, ED3-positive macrophages con-
taining Rh-Lip were MHC-Class II (OX6)-negative (Figure
3F). Fluorescent liposomes internalized by macrophages in
the conjunctiva still contained VIP 24 h following IVT injec-
tion of VIP-Rh-Lip, (Figure 3G), but VIP was not detected in
conjunctival macrophages after IVT injection of Rh-Lip alone
(data not shown). In the choroid, MHC class II-positive den-
dritic cells did not contain any fluorescent liposomes (Figure
3F). The nature and distribution of cells internalizing
rhodamine-conjugated liposomes in the eye was equivalent
when checked at 24 h, seven days (data not shown), and 14
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Figure 4. Biodistribution of rhodamine-
conjugated-liposomes in cervical LN in
healthy rats 24 h following IVT injection
of VIP-Rh-Lip.  A: Following IVT injec-
tion, VIP-Rh-Lip (red) are located within
subcapsular sinus macrophages stained
with ED3 (green). OX6-positive cells in
blue are located in close proximity (ar-
row) with ED3-positive macrophages
containing VIP-Rh-Lip. B: T lympho-
cytes recognized by their TCR expres-
sion (green) are localized in contact (ar-
row) with subcapsular macrophages con-
taining VIP-Rh-Lip (red). C: Subcapsu-
lar sinus macrophages (asterisk) contain-
ing VIP-Rh-Lip (red) express CD4 in
green and are in contact with CD4-posi-
tive lymphocytes (arrow). D: CD8-posi-
tive T lymphocytes (green) are also ad-
jacent with VIP-Rh-Lip (red)-bearing
macrophages. In B, C, and D nuclei are
stained in blue with Toto3®-iodide. All
bars represent 5 µm. Confocal micros-
copy optical sections are 1.5 µm in all
images. Representative images of four
experiments performed on cervical LN
from four rats.
TABLE 2. OCULAR DISTRIBUTION OF RH-LIP AND VIP-RH-LIP ARE
EQUIVALENT
                           Rh-Lip   VIP-Rh-Lip
         Tissue             n=3        n=3
------------------------   ------   ----------
Aqueous humor                -          -
Vitreous                     ++         ++
Inner limiting membrane      ++         ++
Retinal parenchyma           -          -
Iris                         -          -
Ciliary body and muscles     +          +
Conjunctiva                  ++         ++
Episclera                    ++         ++
Ocular and systemic distribution of Rh-Lip-bearing cells 24 h and 14
days following their IVT injections
2268days following IVT injection (Table 2).
Distribution of Rh-Lip in the secondary lymphoid organs
following intravitreal injection of Rh-Lip:  Following IVT in-
jection of Rh-Lip, fluorescent liposomes were observed in
cervical LN as early as 2 h after IVT injection (data not shown).
Twenty-four h and up to 14 days following injection, Rh-Lip
was almost exclusively detected in the subcapsular sinus of
the cervical LN (Table 2). In several places, red fluorescence
was detected in the B cell area of the cervical LN but was not
associated with a specific cell type (data not shown). We hy-
pothesize that this red fluorescence corresponds to a leakage
of rhodamine from adjacent Rh-Lip. A rare cell containing
Rh-Lip was observed in the subcapsular sinus of the mesen-
teric LN of one animal out of three (Table 2), and only a few
cells bearing a limited quantity of Rh-Lip were detected in the
marginal zone of the spleen. No difference was noted in the
biodistribution of unloaded liposomes (Rh-Lip) and liposomes
containing VIP (VIP-Rh-Lip; Table 2).
Localization and phenotypic characterization of Rh-Lip-
bearing cells in the secondary lymphoid organs:  To charac-
terize the nature of the cells that have internalized Rh-Lip in
the secondary lymphoid organs 24 h following their IVT in-
jection, cervical LN and spleen sections were subjected to
immunofluorescent-staining with a range of mAbs specific
for phenotypic markers of macrophages and dendritic cells.
The rare Rh-bearing cells were located in the mesenteric LN
and in the marginal zone of the spleen expressed ED3 (data
not shown), confirming their identity as resident macrophages.
In the cervical LN, Rh-Lip-bearing cells were situated mostly
just underneath the subcapsular sinus. Some of these cells were
also found more deeply within the T cell area and around B
cell follicles. These cells expressed the macrophage markers,
ED1 (data not shown) and ED3 (Figure 4A). These cells failed
to express the dendritic cell marker OX62 (data not shown),
strongly indicating they are subcapsular sinus macrophages
and not dendritic cells [24]. In addition, free rhodamine was
observed in the cervical LN at the level of some B cell fol-
licles, which are generally surrounded by ED3-positive mac-
rophages (not shown). This suggests that liposome degrada-
tion products generated by subcapsular sinus macrophages may
become available to B lymphocytes.
In the cervical LN, we observed numerous small, round
OX6-positive cells in contact with ED3-positive macrophages
containing Rh-Lip (Figure 4A). Subcapsular sinus macroph-
ages surround B cells follicles thus these OX6-positive cells
in contact with Rh-Lip-bearing macrophages are most prob-
ably B cells. In addition, we detected TCR-positive T lym-
phocytes in close proximity with cells that had internalized
Rh-Lip (Figure 4B). Many cells of small size adjacent to Rh-
Lip-containing macrophages expressed CD4 (Figure 4C). Of
note, CD4 is also expressed by subcapsular sinus macroph-
ages (Figure 4C, asterisk) as previously reported for all mac-
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Figure 5. VIP biodistribution in cer-
vical LN 24 h following IVT injec-
tion of VIP-Rh-Lip.  A: Free VIP
(green), detected with rabbit anti-
VIP antibody is localized in the si-
nus (asterisks) and within subcap-
sular sinus macrophages containing
rhodamine-conjugated-liposomes
(red; B to D) Enlargement of the
inset in A is shown in B to D. Free
soluble VIP (green) is detected as
green dots in the LN capsule (aster-
isks) and the LN parenchyma. VIP
(appearing as yellow granules) is
also detected within resident mac-
rophages containing Rh-Lip (red
cells in B and C). VIP is detected in
small round cells that contain only
minute amounts of Rh-Lip (arrows
in B, C, and D). In A to D VIP ap-
pears green, Rh-Lip appears red and
colocalization is indicated in yellow.
Nuclei are stained in blue with
Toto3®-iodide.All bars represent 20
µm, confocal microscopy optical
section is 1.5 µm in all images. Rep-
resentative images of two experi-
ments performed on cervical LN
from two rats.
2269rophages in the rat [23]. Cells expressing CD8 were also ob-
served to be adjacent to Rh-Lip-bearing macrophages (Figure
2D). No difference was noted regarding the nature of the cells
internalizing liposomes and the cellular interactions with B
cells and T cells in the LN in rats receiving Rh-Lip and VIP-
Rh-Lip, respectively.
VIP biodistribution in cervical lymph nodes following an
intravitreal injection of VIP-Rh-Lip:  VIP immunostaining was
performed on frozen sections of cervical LN of normal ani-
mals that received a single IVT injection of VIP-Rh-Lip.
Soluble VIP (green) was detected in the sinus of the LN (as-
terisks in Figure 5A,B,D). In addition, VIP was detected within
large cells containing Rh-Lip corresponding to subcapsular
sinus macrophages (Figure 5A-D). VIP was also detected in
small, round cells (characterized in Figure 6) that contained
only a minute amount of Rh-Lip (arrow in Figure 5B-D) close
to VIP-Rh-Lip-bearing macrophages in the subcapsular sinus.
In animals that received an IVT injection of Rh-Lip that did
not contain VIP, there was no VIP detectable in the subcapsu-
lar sinus of the cervical LN (data not shown). These macroph-
ages expressed ED3 confirming their identity as subcapsular
sinus macrophages (Figure 7A-D). Our results suggest strongly
that VIP travels encapsulated within liposomes from the con-
junctiva (not shown) to the cervical LN (Figure 5A) where it
is phagocytosed by resident macrophages.
To determine the nature of the small cells adjacent to mac-
rophages in the cervical LN in which VIP was detected, triple
immunostaining for VIP (blue), Rh-Lip (red), and T cell mark-
ers (green) were performed. VIP was detected in the capsular
sinus (asterisk in Figure 6A,B,D) and the LN parenchyma (Fig-
ure 6A,B,D). VIP was also detected within VIP-Rh-Lip-bear-
ing macrophages (Ma and Mb in Figure 6A,B,D) and in CD8-
positive T cells (arrows in Figure 6A,C,D). In addition, VIP
was present in macrophages (Mc, Figure 5E) containing Rh-
Lip (Figure 6F) and in small cells expressing CD4 (arrow in
Figure 6G,H). This result strongly suggests that the small cells
immuno-positive for VIP are CD4 and CD8-positive T lym-
phocytes. The T lymphocyte nature of these cells was con-
firmed by their expression of TCR (data not shown).
DISCUSSION
 Liposome encapsulation of pharmaceutical molecules is of
great interest for efficient drug delivery to intraocular tissues
[8-11]. However, distribution studies of liposomes are needed
to optimize ocular disease therapies. In the present study, we
show that following IVT injection in healthy Lewis rats, free
rhodamine-conjugated liposomes (Rh-Lip) and cells bearing
liposomes were located mainly in tissues of the posterior seg-
ment of the eye, namely the vitreous and inner layers of the
retina. The distribution of Rh-lip in the eye was equivalent at
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Figure 6. VIP detection in CD4 and CD8-positive T-cells in the cervical LN of rats receiving an IVT injection of VIP-loaded-rhodamine-
conjugated-liposomes.  A-D: Immuno-detection of VIP as blue dots in the LN capsule (asterisk), the LN parenchyma, within VIP-Rh-Lip-
bearing macrophage (Ma) but also within macrophages that do not contain VIP-Rh-Lip (Mb, arrowhead): compare the localization of VIP in
A, with the localization of VIP-Rh-Lip in red (B). VIP is present at the membrane of CD8-positive T lymphocytes in green (arrows): compare
image A and C. Note the presence of a neutrophil (N) in B and D containing Rh-Lip in contact with macrophage Ma. VIP is present in small
cells expressing CD4 in green (arrows; G,H) in the vicinity of macrophages containing Rh-Lip (Mc; E,F). In A to H, VIP is in blue, Rh-Lip in
red, T cell markers in green and colocalization is in purple. All bars represent 20 µm, confocal microscopy optical section is 1.5 µm in all
images. Representative images of two experiments performed on cervical LN from two rats.
227024 h, seven days, and 14 days (Table 2 and data not shown),
but the amount of intraocular liposomes decreased with time.
We noted the presence of free rhodamine within the in-
ternal layers of the retina suggesting that a release of free VIP
could occur at this level. Indeed, we have shown previously
[21] that VIP released from liposomes at the level of the inner
retina enters the retina passively, potentially modulating the
immunological properties of both retinal Müller glial cells and
microglia.
In the present study, an uptake of Rh-Lip by activated
retinal Müller glial cells was observed. Müller glial cells are
giant cells spanning the full thickness of the retina from the
internal to the external limiting membranes, their end feet lie
along the internal limiting membrane in close contact with the
vitreous and the retinal blood vessels. These cells have been
shown to be involved in modulation of the ocular immune
responses during uveitis [25,26]. Moreover, Müller glial cells
transduced ex vivo with adenovirus expressing viral IL-10
(vIL-10) and injected IVT to recipient animals, induced the
expression of vIL-10 in ocular tissues and media, and reduced
the pathological manifestations of experimental autoimmune
uveoretinitis (EAU) [27]. We hypothesize that liposome up-
take by retinal Müller glial cells could contribute to extended
intraocular drug delivery and participate in the modulation of
ocular inflammation. In contrast, liposomes were poorly in-
ternalized by microglia, by cells located in the choroid, or by
retinal pigmented epithelial (RPE) cells. This observation is
consistent with our previous findings showing that following
IVT injection of liposomes loaded with oligonucleotides in
rabbits, more than 70% of the oligonucleotides were detected
at 24 h in the vitreous while less than 5% was detected in the
retina choroid, lens, and sclera [28]. The limited retinal pen-
etration by liposomes is either due to their size or pharmaceu-
tical properties. The size of liposomes used in this study var-
ies between 250 and 400 nm for Rh-Lip and 300 and 600 nm
for VIP-Rh-Lip [21]. Smaller liposomes (less than 100 nm)
can easily be produced, but VIP encapsulation in these small
liposomes by the lyophilization-rehydration method leads to
the increase of liposome size. Other encapsulation methods
were unfeasible because it destroyed VIP [22]. To optimize
therapeutic strategies based on IVT injection of liposomes,
we propose to inject a mix of different size liposomes con-
taining various therapeutic molecules. This could result in the
specific targeting of macrophages in the vitreous and Müller
cells at the level of the inner limiting membrane of the retina
by VIP-loaded large liposomes (300-600 nm). At the same
time, other molecules encapsulated in small liposomes (less
than 100 nm) could reach the outer segments of the retina and
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Figure 7. VIP-loaded rhodamine-
conjugated-liposomes (VIP-Rh-lip)
internalization and VIP expression
by ED3-positive macrophages in
cervical LN 24 h following IVT in-
jection of VIP-Rh-Lip.  A: Free VIP,
detected with rabbit anti-VIP anti-
body (blue) localized within cells
containing Rh-Lip (red; B) and ex-
pressing ED3 green (C). D: Merge
image showing membranous ex-
pression of ED3 by cells containing
Rh-lip and blue granules within li-
posomes. The bar in D represents 20
µm in all images. Confocal micros-
copy optical section is 2 µm in all
images. Representative images of
two experiments performed on cer-
vical LN from two rats.
2271the RPE and thus protect photoreceptors from degeneration.
Pharmacological and therapeutic studies need to be performed
to determine the efficacy of this method.
We have previously shown that intravitreal injection of
liposomes loaded with VIP successfully reduced ocular in-
flammation induced by subcutaneous injection of LPS (en-
dotoxin-induced uveitis, EIU), a non-specific ocular inflam-
mation of short duration [21]. In the present paper, we have
checked with precision the ocular and immune system
biodistribution of rhodamine-conjugated liposomes in healthy
animals. No difference in distribution in the lymphoid organs
was found between healthy animals and EIU rats [21]. More-
over, biodistribution of rhodamine-conjugated liposomes in
the posterior segment of the eye was identical in healthy rats
as shown in the present work and in EIU rats [21]. However,
in animals with EIU, liposomes were also internalized in the
anterior segment by infiltrating neutrophils and macrophages.
This phenomenon is probably partly responsible for the thera-
peutic effect of the IVT injection of VIP-Lip during EIU [21].
In contrast, only few liposomes were detected in the anterior
segment of healthy rat eyes where there are no inflammatory
cells.
The intraocular biodistribution of rhodamine-conjugated
liposomes following their IVT injection reported here differs
widely from the biodistribution of fluorescent Ag injected into
the AC of the eye reported previously [1,3,5]. Indeed, follow-
ing an intracameral injection, fluorescent Ag were detected in
cells located preeminently in tissues lining the AC of the eye,
namely the cornea, iris, and ciliary body [1,3,5]. Ag then
reached the venous circulation via the trabecular meshworks
and Schlemm’s canal, and a large quantity of fluorescent Ag
was captured by macrophages in the marginal zone of the
spleen and mesenteric LN [1,3-5]. However, in the present
study, very few liposomes injected into the vitreous were de-
tected, either free or taken up by cells, in the anterior segment
of the eye, and only rare macrophages containing liposomes
were observed in the spleen. We propose that only limited
amounts of liposomes were drained out of the vitreous via the
AC and Schlemm’s canal (conventional aqueous outflow path-
way), and thus very few liposomes reached the marginal zone
of the spleen of IVT injected rats. We have previously shown
that polystyrene and cyanoacrylate nanoparticles [29] injected
into the vitreous were able to enter the anterior segment of the
eye, to accumulate in Schlemm’s canal, and to leave the eye
via the venous circulation. This suggests that size and physico-
chemical properties of molecules and particles injected into
the vitreous influence their egress pathway from the eye.
In the present study, we found large amounts of IVT-in-
jected Rh-Lip internalized by macrophages in the conjunctiva
and then in subcapsular macrophages in the cervical LN even
14 days following the IVT injection ([21] and Table 2). We
have previously demonstrated that Ag placed into the AC of
the eye can access the conjunctiva via the nonconventional
aqueous outflow pathway and from there reach the cervical
LN via conjunctival lymphatic vessels [30,31]. In the present
study, Rh-Lip drainage to the cervical LN more probably re-
sults from Rh-Lip deposition in the conjunctival tissue occur-
ring during the IVT injection itself.
In summary, the present fluorescent liposome
biodistribution study shows that (1) most liposomes stay in
the vitreous and show limited penetration in the retina where
they are mostly internalized by retinal Müller glial cells but
not by microglia; (2) only few Rh-Lip placed into the vitreous
body leave the eye via the conventional outflow pathway
through Schlemm’s canal, and consequently, few reach the
venous circulation and are internalized by marginal zone mac-
rophages in the spleen; and (3) the fluorescent liposomes de-
posited in the conjunctiva during IVT injection access the cer-
vical LN via lymphatic vessels in the conjunctiva.
As previously reported following intracameral injection
of fluorescent Ag, VIP-Rh-Lip were internalized in the cervi-
cal LN by subcapsular sinus macrophages expressing ED3
[4,5,32]. The VIP-loaded macrophages are in contact with OX6
(probably B cells) and TCR-, CD4- or CD8-positive T cells in
the cervical LN. No liposome uptake by OX62-positive den-
dritic cells in the cervical LN was observed (data not shown).
Internalization of VIP-Rh-Lip by macrophages in the cervical
LN in vivo could alter and modify their function from inflam-
matory macrophages to regulatory macrophages. Moreover,
macrophages internalizing VIP-Rh-Lip could participate in the
slow release of VIP in the LN, possibly changing the LN im-
mune environment over a long period of time. A large quan-
tity of VIP was detected as free molecules in the subcapsular
sinus of the LN. VIP observed within the LN parenchyma was
also probably associated as free peptide with the reticular net-
work of high endothelial venules in the LN as previously de-
scribed following subcutaneous injection of small molecules
and chemokines [31,33]. Free VIP associated with the reticu-
lar network of high endothelial venules in the LN can modu-
late immune function of macrophages, dendritic cells, and B
and T lymphocytes [18]. In the cervical LN of VIP-Rh-Lip
injected rats, VIP was detected in T lymphocytes. VIP diffus-
ing from VIP-Rh-Lip contained in ED3-positive macrophages
could induce VIP production in adjacent T cells. Indeed, T
cells express VPAC1 and VPAC2, two of the three VIP recep-
tors [34]. Thus, VIP detected in T lymphocytes could either
represent VIP attached to its membranous receptor or VIP pro-
duced by T cells in response to VIP stimulation as previously
reported [35]. VIP immunoreactivity in macrophages and T
cells in the cervical LN suggests that a single IVT injection of
liposomes loaded with VIP could modulate the loco-regional
ocular immune response and thus reinforce the ocular immune
privilege [13].
In conclusion, an IVT injection of VIP encapsulated within
liposomes provides long-term expression of VIP inside the
eye and in the cervical LN draining the eye. The resulting
potential modulation of the loco-regional immune microenvi-
ronment suggests that a single IVT injection of VIP-Lip is a
rational therapeutic modality for posterior uveitis and other
immune-mediated ocular diseases in humans.
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